GHRP-2 + Ipamorelin Blend
Also known as: Dual GHS blend
GHRP-2 + Ipamorelin Blend (also called Dual GHS blend) is a research peptide in the Growth Hormone Secretagogue class. This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- Mixture
- Half-life
- Short; both ~1–2 h combined activity
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GHSR
Research summary
Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's GHRP-2 + Ipamorelin Blend profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
GHRP-2 + Ipamorelin Blend dosage: no established human dose
The GHRP-2 and ipamorelin blend has no established human dosage. No human study has tested the two together. Each has been given to people on its own, but only as single or short-term intravenous doses: GHRP-2 as a 100 mcg bolus in a growth hormone stimulation test, and ipamorelin as weight-based infusions in a pharmacokinetic study and a post-surgery trial.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: GHRP-2 and ipamorelin both act on the same target, the growth hormone secretagogue (ghrelin) receptor. Human data for each comes from short intravenous studies of that compound alone. No study, human or animal, of the two given together was found in PubMed or ClinicalTrials.gov, so there is no dose, safety or outcome data for the combination.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — GHRP-2 (pralmorelin): vasopressin secretion study in healthy men (2010)Clinical trial · Human endocrine physiology study of one component aloneStudied an analog, not GHRP-2 + Ipamorelin Blend itself | 10 healthy men, tested fasting and non-fasting | 100 mcg of GHRP-2 alone | Intravenous bolus | Single dose | Sampling at 15, 30, 45 and 60 minutes | Growth hormone, ACTH and prolactin rose, with higher peaks when fasting; vasopressin was not stimulated | GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010. |
| Component (analog evidence) — ipamorelin: human pharmacokinetic study (Gobburu et al., 1999)Clinical trial · Human dose-escalation PK/PD study of one component aloneStudied an analog, not GHRP-2 + Ipamorelin Blend itself | Healthy male volunteers, 8 per dose level | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg of ipamorelin alone (dose escalation) | Intravenous infusion over 15 minutes | Single dose per level | Single 15-minute infusion | Dose-proportional pharmacokinetics, terminal half-life about 2 hours, and a single episode of growth hormone release at every dose | Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. |
| Component (analog evidence) — ipamorelin: phase 2 trial in post-operative ileus (Beck et al., 2014; NCT00672074)Clinical trial · Phase 2 double-blind randomised placebo-controlled trial of one component aloneStudied an analog, not GHRP-2 + Ipamorelin Blend itself | Adults after small or large bowel resection (117 enrolled, 114 analysed) | 0.03 mg/kg of ipamorelin alone | Intravenous infusion | Twice daily | Postoperative day 1 to day 7, or until discharge | No significant difference from placebo in time to first tolerated solid meal (p = 0.15) | Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. |
Where sources disagree
- A blend's amount of GHRP-2 or ipamorelin is not a dose that was studied for that compound. The human doses for each are single intravenous doses, not repeated injections under the skin. See the GHRP-2 (pralmorelin) and Ipamorelin profiles.
- GHRP-2 raised ACTH and prolactin as well as growth hormone in the human study cited here. That is a property of the GHRP-2 component, and it is not removed by mixing it with ipamorelin.
- No shop listing for this blend as a vial was found, so no vial sizes are given.
Handling & administration
- Timing Notes
- Used together to increase GH/IGF axis stimulation in research.
Sequence & molecular data
| Molecular formula | Mixture of C45H55N9O6 (GHRP-2) and C38H49N9O5 (Ipamorelin) |
|---|---|
| Molecular weight | Mixture |
| Half-life | Short; both ~1–2 h combined activity |
| Appearance | White lyophilized powder blend |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy. The practical consequence is that the profile shifts toward that of the less selective component: GHRP-2 raises ACTH, cortisol and prolactin more than ipamorelin does, so the combination tends to carry more of those effects than ipamorelin alone while offering no new pharmacological pathway. No controlled human data exists for this specific combination.
Origin
Combination of two synthetic GHRPs.
Targets
Studies
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN (component evidence (pralmorelin (ghrp-2)))
- Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial (component evidence (pralmorelin (ghrp-2)))
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (component evidence (ipamorelin))
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism (component evidence (ipamorelin))
Regulatory & research status
GHRP-2 + Ipamorelin Blend is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
GHRP-2 + Ipamorelin Blend side effects
GHRP-2 + Ipamorelin Blend has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Hunger
- Cortisol/prolactin rise from GHRP-2
- Water retention
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
GHRP-2 + Ipamorelin Blend: frequently asked questions
What is GHRP-2 + Ipamorelin Blend?
Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.
How does GHRP-2 + Ipamorelin Blend work?
This blend combines two agonists at the same receptor, growth hormone secretagogue receptor 1a. Because both act at that single target, combining them does not recruit an additional mechanism the way pairing a secretagogue with a GHRH analog does; it primarily increases total receptor occupancy.
Is GHRP-2 + Ipamorelin Blend FDA approved?
No. GHRP-2 + Ipamorelin Blend is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of GHRP-2 + Ipamorelin Blend?
Reported half-life for GHRP-2 + Ipamorelin Blend is Short; both ~1–2 h combined activity. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is GHRP-2 + Ipamorelin Blend banned in sport?
GHRP-2 + Ipamorelin Blend is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to GHRP-2 + Ipamorelin Blend?
Compounds most often compared with GHRP-2 + Ipamorelin Blend include Ipamorelin, GHRP-6, GHRP-1 and Pralmorelin (GHRP-2). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Component evidence (Pralmorelin (GHRP-2)) — Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LNExternal reference
- Component evidence (Pralmorelin (GHRP-2)) — Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vialExternal reference
- Component evidence (Ipamorelin) — The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicusExternal reference
- Component evidence (Ipamorelin) — The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanismExternal reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This GHRP-2 + Ipamorelin Blend profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track GHRP-2 + Ipamorelin Blend research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →